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Abstract 
Back ground and Aims: Conventional risk factors like age, gender, blood lipids, hypertension and 
smoking have been the basis of coronary artery disease (CAD) risk prediction algorithms, but provide 
only modest discrimination. A genetic risk score (GRS) may provide improved discrimination over 
and above conventional risk factors alone. The current study analysed the genetic risk of CAD in 
Pakistani subjects using a GRS of 21 loci in 18 genes and examined whether its association with blood 
lipids in this cohort. 
Methods: 625 subjects were genotyped for the variants, NOS3 rs1799983, SMAD3 rs17228212, 
APOBrs1042031, LPArs3798220, LPA rs10455872, SORT1rs646776, APOE rs429358, GLUL 
rs10911021 and FTO rs9939609 (by TaqMan) and MIA3 rs17465637,CDKN2A rs10757274, DAB2IP 
rs7025486, CXCL12 rs1746048, ACE rs4341, APOA5 rs662799, CETP rs708272, MRAS rs9818870, 
LPL rs328,LPL rs1801177, PCSK9 rs11591147and APOE rs7412 (by KASPar technique). 
Results: Individually, risk allele frequencies were not significantly higher in cases than controls 
(p>0.05) except for APOB rs1042031 and FTO rs9939609 (p=0.007 and 0.003 respectively), and did 
not associate with CAD except rs1042031 and rs993969 (p=0.01 and 0.009 respectively). However, 
the GRS of 21 SNPs was significantly higher in cases than controls (17.53±2.52 vs16.64±2.44, 
p<0.001) and was associated with CAD risk. CAD risk in the top quintile of GRS was 2.96 (95% CI 
1.71-5.13).  Atherogenic blood lipid levels showed significant positive association with GRS.  
Conclusion: The GRS was quantitatively associated with d CAD risk and showed association with 
blood lipid levels, suggesting that the mechanism of these variants is likely to be in part at least 
through creating an atherogenic lipid profile in subjects carrying high numbers of risk alleles. 
Key words: Coronary artery disease, Genetic risk score, conventional risk factors  
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Introduction 
Coronary artery disease (CAD) is a chronic disorder progressing silently and usually has 
established to an advance stage by the time symptoms start appearing. Despite all measures, 
CAD remains the single largest killer worldwide. In high income countries, the CAD 
mortality rate has declined since 1980 and has shifted to an older age group, whereas, middle 
and low income countries bear three quarters of the global CAD burden. South Asians are at a 
greater risk and the prevalence is 50% to 300% higher than rest of the world (Enas & Kannan, 
2005). The prevalence of CAD is even higher in Pakistan (Jafar, Jafary, Jessani, & 
Chaturvedi, 2005) with more than 30% of the population above 45 years of age being affected 
by the disease (Gaziano, Bitton, Anand, Abrahams-Gessel, & Murphy, 2010). The disease 
burden has almost doubled in urban Karachi since 1970 (Aziz, Uddin, Faruqui, Patel, & 
Jaffery, 2012). According to latest WHO reports, cardiovascular diseases (CVD) are among 
the biggest non-communicable killers in Pakistan and CAD represents a major type of CVD 
(http://www.who.int/countries/pak/en/). 
CAD is a multifactorial disorder and arises from an interaction between environmental and 
genetic factors. The identifiable environmental risk factors have been identified in about 80% 
of CAD cases (Alwan, 2011). Most of the CAD risk factors are modifiable therefore to target 
life style changes or for drug intervention, those who are at most risk of developing disease 
should be properly identified. The conventional CAD risk factors (CRFs) like age, gender, 
blood lipids, smoking, blood pressure and diabetes have been the basis of CAD risk prediction 
algorithms developed by many consortia. These risk prediction algorithms  include the 
Framingham risk score (Wilson et al., 1998), the Prospective Cardiovascular Munster Heart 
Study (PROCAM) (Assmann, Cullen, & Schulte, 2002), the Systematic Coronary Risk 
Evaluation (SCORE) system (Conroy et al., 2003), the Reynolds risk score (Ridker, Buring, 
Rifai, & Cook, 2007) and QRISK2 (Hippisley-Cox et al., 2008). These CRF algorithms 
calculate 10 years CAD risk and the individuals are then classified according to their risk. The 
high risk category individuals qualify for the preventive treatment (statin), and until recently, 
the cut-off for statin treatment has been set at 20% 10 years CAD risk (Wood et al., 2005). 
Lower cut-off value has been proposed in both UK and USA (10% and 7.5% respectively). 
The use of CAD risk prediction scores has increased the average life time of CAD patients by 
three years in USA (Lenfant, 2003). However, the risk assessment using CRFs provide only 
modest discrimination and do not fully explain the underlying risk (Wang et al., 2006). These 
scores lack accuracy and may overestimate risk in low risk subjects or underestimate risk in 
subjects at high risk (Brindle, Beswick, Fahey, & Ebrahim, 2006; Wilson et al., 1998). 
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Almost 15-20% cases who developed the disease in their later life were underestimated 
(Thanassoulis & Vasan, 2010) with most of the cases occurring in intermediate and low risk 
subjects (Collins & Altman, 2009; Cooper, Miller, & Humphries, 2005). 
The variability in disease susceptibility in individuals exposed to similar environmental 
factors and having almost same CRFs can be attributed to the genetic variations (Stranger et 
al., 2007).Genetic testing may improve discrimination over and above the CRFs. Family 
history of early heart disease has long been a known CAD risk factor and heritability of CAD 
has been estimated to be more than 40% (Peden & Farrall, 2011). Historically, the genetic risk 
of a disease was assessed through the presence of the disease in the proband’s relatives and 
the genetic component was described as heritability estimate. Then the ‘candidate gene’ 
approach was used, where common variants were determined in the genes regulating 
biochemical pathways of disease pathogenesis (Wray & Goddard, 2010). Since 2007, 
additional genes associated with CAD have been identified by Genome Wide Association 
studies (GWAS) (I. K. C. Consortium, 2011). Single nucleotide polymorphisms (SNPs) can 
be used as markers of genetic variability. The CAD associated SNPs are common in the 
general population with a minimal to moderate relative risk. Most of them  are located in non-
coding DNA region implying that they influence by regulating the expression of upstream or 
downstream genes. Another striking feature of CAD risk SNPs is that most of them operate 
independently of known CAD risk factors. This indicates that many unknown pathways 
involved in development of CAD still need to be explored (Folkersen et al., 2010). However, 
the risk associated with single SNP is modest, because of the low effect sizes of common 
variants, and therefore a large number of SNPs need to be genotyped for the genetic analysis 
of CAD like complex disease. 
A genetic risk score (GRS) of a disease is calculated by summing up the number of risk 
alleles at all the loci included in the genetic risk of that disease. The GRS is a multi-locus 
profile used to transpose the discoveries from candidate gene studies and GWASs into 
population health tools (Belsky et al., 2013; Fava et al., 2014). A GRS summarizes the effect 
of multiple variants in a quantitative manner and hence is superior over the predictive power 
of a single SNP. The use of GRS information into risk prediction of CAD can bridge up the 
genomic research with more applied clinical practice. Different researchers have used varying 
number and types of loci for inclusion in CAD genetic risk scoring, the number ranging from 
less than 10 to more than 100 (Anderson et al., 2010; Paynter et al., 2010; Qi et al., 2011; 
Ripatti et al., 2010; Thanassoulis et al., 2012). 
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The majority of genetic studies and GWAS have been conducted on European/Caucasian 
people. It remained a routine practice to transpose the results obtained from such studies 
conducted in developed countries to the rest of the world, but there remains an immense 
requirement to extend genetic studies to other ethnicities also. The allele frequencies of many 
common variants vary widely between ethnicities. For example, the association of the 9p21 
region with CAD has not been replicated in African Americans (Assimes et al., 2008; 
McPherson et al., 2007). Similarly, the linkage disequilibrium and effect size of common 
variants may vary across ethnicities. Moreover, a genetic marker may not be associated with a 
trait in all ethnicities and in such cases the applicability is limited to only those populations 
where the genotype to phenotype association is clearly seen (Ioannidis, 2009). The Pakistani 
population, like other Asian countries is under represented in international genetic studies like 
HAP MAP or 1000 genomes project. To date the genetic architecture of CAD has not been 
evaluated properly for this population. A preliminary report of the use of a 19 SNPs GRS in 
CAD risk analysis in the Pakistani subjects has been published (Beaney et al., 2015), but the 
study was underpowered to detect the same effect as observed in Europeans. In the current 
study, we included two additional SNPs to construct a CAD GRS and increased the sample 
size. We hypothesized that to predict CAD risk; the GRS of 21 SNPs will be superior over 
single SNPs having small effect size and modest association. 
 
Materials and methods 
The study comprised of 405 diagnosed cases of CAD and 220 healthy controls. The selection 
criteria for the subject recruitment has been described previously (Shahid, Cooper, Rehman, 
& Humphries, 2016). The CAD cases were recruited from tertiary care hospitals in Lahore 
during February 2012 to June 2013. These selected subjects had suffered from a non-fatal 
myocardial infarction, with  diagnosis of myocardial infarction made by the consultant 
cardiologist based on the reports of ECG, cardiac echo, angiography, troponine T/I and 
clinical history. Only those CAD cases were selected which were recently diagnosed and had 
not started lipid lowering or antihypertensive drugs therapy. The controls were apparently 
healthy subjects, not having any family history of CAD. It was taken care that cases and 
controls represented all the socioeconomic groups.  Subjects with obesity (BMI> XXX) were 
also excluded from the study but not those with Type 2 diabetes because  the number of CAD 
subjects with type 2 diabetes was high and the sample size would have become too small to 
have adequate power. All participants gave a written informed consent. The study was 
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approved by the ethics committee, University of the Punjab, Lahore and all the procedures 
were in compliance with the Helsinki declaration. 
Genotyping 
The DNA was extracted from whole blood leucocytes using  Wizard genomic DNA 
purification Kit (Promega, USA). The DNA samples were quantified using nanodrop (ND-
8000, USA). The concentration of DNA samples was standardized to 1.25ng/ul. The 
genotyping was carried out in specially designed 384 well plates (Micro Amp). The DNA 
samples were arrayed by an automated robotic liquid handling system (Biomerk-FX, 
Beckman Couter). Two high throughput florescent based genotyping techniques, TaqMan and 
KASPar, were used for genotyping the SNPs. The details of genotyping techniques have been 
given somewhere else (Shahid, Cooper, Beaney, et al., 2016). The information on SNPs 
included is provided in supplementary table 1. 
The SNPs NOS3 (rs1799983), SMAD3 (rs17228212), APOB (rs1042031), LPA (rs3798220), 
LPA (rs10455872), SORT1 (rs646776), APOE (rs429358), GLUL (rs10911021) and FTO 
(rs9939609) were genotyped by TaqMan technique using qPCR master mix (KAPA 
Biosystems, USA). The SNPs MIA3 (rs17465637), CDKN2A (rs10757274), DAB2IP 
(rs7025486), CXCL12 (rs1746048), ACE (rs4341), APOA5 (rs662799), CETP (rs708272), 
MRAS (rs9818870) LPL (rs328), LPL (rs1801177), PCSK9 (rs11591147) and APOE (rs7412) 
were genotyped by KASPar technique with touchdown thermal cycler programme. The SNP 
LPL (rs1801177) was monomorphic in this population but data from this SNP is shown for 
completeness. The list of primers and probes used for TaqMan and KASPar are given in 
supplementary tables 2 and 3 respectively. After amplification, the results were analysed on 
ABI Prism 7900HT (Applied Biosystems/Life Technologies) and the genotypes were called 
using sequence detection software (SDS), version 2.0. The quality check of genotyping 
techniques was maintained by the inclusion of non-template controls (NTCs). There were 16 
NTCs included in each plate of 384 wells. Only those runs were included in the analysis 
where none of the NTCs crossed the amplification cut-off line. Only the samples which were 
clearly clustered were included in the study. While genotyping the variants with very low risk 
allele frequency like APOE rs7412, LPA rs3798220, LPA rs10455872 and LPL rs1801177, 
known heterozygotes were added to avoid false negative calls.  The genotypes were also 
randomly confirmed by the conventional direct DNA sequencing, and  10-15% of samples 
from each run were outsourced (source biosciences, UK) for direct sequencing and the results 
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were always similar to that of TaqMan/KASPar. The list of primers used for direct DNA 
sequencing is given in supplementary table 4. 
Statistical analysis 
The results were statistically analysed using statistical package for social sciences (SPSS) 
IBM, version 22. The continuous variables were compared between cases and controls using 
independent sample student t test. Hardy Weinberg equilibrium was accessed by a χ² 
goodness of fit test. The categorical variables such as risk allele frequencies (RAFs) were 
compared between cases and controls by χ² test. All the analyses were adjusted for age, 
gender, BMI, hypertensive and diabetic status. Since CAD is a binary variable, the association 
of the SNPs with CAD was examined using binary logistic regression. The effect of 
increasing GRS values on CAD was calculated through GRS quintile analysis. The 
distribution of GRS in cases and controls was compared visually by histograms. The power of 
the GRS to discriminate between CAD cases and controls was examined by receiver operative 
curve (ROC) analysis. Blood lipid levels across different number of risk allele in GRS were 
calculated by one way analysis of variance (ANOVA). The effect size/beta effect which is per 
risk allele effect of of GRS on lipid levels was calculated by linear regression.  
Constructing a GRS 
The un-weighted GRS was calculated by simply summing up the number of risk alleles at all 
the loci included in the study. The risk alleles were considered to be acting in additive manner 
i.e., each risk allele had equal contribution to the outcome and each risk allele was coded as 1. 
So the protective homozygous genotype with no risk allele was coded 0, heterozygous 
individual carrying one risk and one normal allele was coded as 1 and the risk homozygous 
individual having both risk alleles was coded as 2. In this way the GRS of an individual can 
range from 0 (no risk allele) to 42 (with all the alleles being risk alleles for 21 loci). 
 
Results 
The baseline biochemical and anthropometric parameters of the subjects under study are 
given in supplementary table 5. The cases were more diabetic and hypertensive, smoking rate 
was also high in cases than controls. Total cholesterol (TC), triglycerides (TG) and LDL-C 
were significantly higher whereas, HDL-C was lower in cases than controls. Individually, the 
RAFs of the studied SNPs were higher in CAD cases compared to controls but the difference 
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was only statistically significant (p<0.05) forAPOB rs1042031 and FTO rs9939609. The 
RAFs in cases versus controls, the p-values for statistical difference between frequencies and 
confidence interval (C.I) are shown (supplementary Table 6). 
The association of SNPs with CAD was assessed by deriving their odds ratios (OR). The 
CAD odds of all the SNPs were greater than 1 (except APOE rs7412) but were not 
statistically significant in the studied sample size. Only,APOB rs1042031 and FTO rs9939609 
were significantly associated with CAD (Table 1). However, the GRS of 21 SNPs was 
significantly higher in CAD cases than controls and was also significantlyassociated with 
CAD risk (supplementary Table 7).The GRS quintile analysis showed that the increase in 
GRS was significantly associated with CAD as shown by inter-quintile p value for CAD 
association. Compared to those in the bottom quintile of the score, CAD risk in the top quintile 
of the GRS was 2.96 (95% CI 1.71-5.13) (Table 2).   
The GRS in whole sample set including cases and controls was normally distributed 
(Supplementary Fig. 1). The GRS histogram for cases exhibited a shift to the right with higher 
GRS values more prevalent. Comparatively, a left shift of GRS was observed in controls with 
the lower GRS being more prevalent. The most prevalent GRS in controls was 17 and 40% 
individuals had this value. In cases, 18 GRS was the most prevalent, present in 65% subjects 
followed by GRS value of 19 which was present in 60% subjects. Similarly, the upper GRS 
quintiles were more prevalent in cases and lower quintiles were more prevalent in controls 
(Fig. 1).  A ROC analysis was conducted to estimate whether the gene score had potential to 
discriminate between cases and controls. The ROC was discriminating between cases and 
controls and the area under ROC was 0.602 (0.56-0.65) which was statistically significant 
(p<0.001) (Supplementary Fig. 2). 
The mean lipid levels along different GRS values are shown in table 3. There is  a significant  
increase in atherogenic lipids and a decrease in atheroprotective lipids with increase in gene 
score. The mean TC, LDL-C and TG increased and HDL-C decreased with gene score. The 
effect size of GRS on TC was 3.7±0.7mg/dl i.e. addition of each risk allele in GRS increased 
TC by 3.7±0.7mg/dl.The effect size of GRS on LDL-C was 4±0.5mg/dl which was 
statistically highly significant. Similarly, lower HDL-C values were observed towards higher 
GRS levels and the effect size of GRS on HDL-C was 2±0.3mg/dl which was a decrease in 
HDL-C per risk allele held by that individual. Similarly, TG levels increased with increase in 
GRS and the effect size of each risk allele in GRS on TG was 4.2±1mg/dl (Table 4). 
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Discussion 
The genetics of complex diseases like CAD is an interplay of different factors because the 
outcome is probabilistic by definition. The statistical parameters which have been used 
include risk prediction (relative risk, odds ratio, hazard ratio), family analysis (liability, 
threshold models) and regression (linear/logistic) (Cordell, 2009). The potential validity of a 
GRS can be examined on the merits of discrimination, risk reclassification and its clinical 
utility. However, due to modest risk associated with individual variants, low power of 
discrimination and lack of replication in different ethnicities, the genetic analysis could 
explain only a small part of heritability, leaving their clinical utility questionable (Carreras-
Torres et al., 2013). In the present study, we have studied SNPs at 21 loci to examine their 
combined effect and utility in genetic risk analysis in the Pakistani population and the 
combined GRS was significantly higher in cases than controls and was associated with CAD. 
There was a graded and continual increase in CAD risk with increasing number of CAD risk 
SNP alleles carried and individuals in the top quintile of the GRS had a CAD risk of 2.96 (95% CI 
1.71-5.13). Even though the score distribution overlaps between cases and controls, the GRS is 
significantly associated with CAD risk and as such can be used as a tool to identify subjects at 
highest risk for lifestyle or therapeutic interventions. 
 
The approach of using a GRS in CAD risk analysis is relatively new in Pakistani subjects; 
however, their use is well established in western countries. In the developed countries where 
CAD CRFs of people are well documented and monitored, CAD risk prediction algorithms 
based on CRFs are available. The GRS in these subjects can then be examined to check 
whether the inclusion of genetic risk information is able to improve the risk prediction over 
and above CRFs. In Pakistani subjects, data on routine CRF monitoring was not available and 
we used the GRS to examine whether it improves the discrimination power over the use of 
single SNPs. 
These SNPs except GLUL rs10911021 and FTO rs9939609 were previously genotyped as a 
group in NPHSII and the 19 SNPs GRS is available for use in CAD risk prediction along with 
10 years Framingham risk score in UK (Beaney et al., 2015). The SNPs included in this study 
were taken from meta-analysis of candidate gene studies (mostly belonging to lipid 
metabolism genes) or were CAD GWAS hits. All the included SNPs were not in LD even if 
present in the same gene.  
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The rationale behind selecting rs9939609 is that it has been reported that the presence of two 
alleles at the rs9939609 site of the FTO gene increased BMI by about 1 kg/m2, body mass by 
2.3Kg and 1.3-fold higher risk of overweight and obesity in both adults and children. It has 
been estimated that per unit increase in BMI increase cardiovascular disease morbidity by 8% 
(Li et al., 2006). However, we found significant association of the risk allele of rs9939609 
with CAD in Pakistani subjects independent of BMI (Shahid, Shabana, Rehman, & Hasnain, 
2016). The variant rs10911021 is a new locus identified to be associated with diabetes in 
subjects with coronary heart disease (Qi et al., 2013). Since its identification, only a few 
studies have investigated its role in different diseases. One study identified this variant to be a 
predictor of all cause mortality in diabetic subjects (Prudente et al., 2015). This intergenic 
SNP is approximately 270 Kb from the gene encoding glutamate ammonia ligase (GLUL) 
enzyme belonging to the glutamine synthase family. It has been found that individuals 
homozygous for the risk allele (C) have a lower plasma pyroglutamic acid/glutamic acid ratio 
resulting in impairment of the γ-glutamyl cycle which consequently increases oxidative 
predisposing diabetic individuals to CHD (Qi et al., 2013). We have confirmed the association 
of this SNP with CHD in subjects with T2D but not non-diabetic subjects (Beaney et al 2016)  
but have no further information on the possible risk mechanism of this SNP. .  
When tested directly for CAD risk prediction , different  GRSs have  shown varying results in 
different  studies. In a study using 24 variants in a sample of European ancestry, the authors 
failed to prove an association between GRS and subclinical atherosclerosis (Hernesniemi et 
al., 2012).  A GRS including 101 variants failed to improve the prediction over and above 
family history (Paynter et al., 2010). Recently, a GRS including 13 SNPs was reported to be 
associated with CAD (Mehta & N, 2011) and in another study GRS of 6 lipid metabolic genes 
improved the discrimination of angiographically proven coronary disease (Anderson et al., 
2010). Similarly in another study, a 13 SNPs score was associated with the first MI event 
(Ripatti et al., 2010). While some researchers were able to improve the net reclassification by 
the inclusion of GRS, the improvement remained modest (Davies et al., 2010; Lluís-Ganella 
et al., 2010), and even some failed to show a significant change in net reclassification 
index(Paynter et al., 2010; Ripatti et al., 2010). 
In this study, the GRS was calculated assuming that all the SNPs had equal effect on the 
outcome and worked additively. However, this may not always be the case because the effect 
size of some SNPs is relatively high while some have more modest effects. This problem may 
be solved by the use of an externally weighted GRS, where the coded genotype is first 
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multiplied by an already estimated effect size of that SNP from a large study,  such as a meta-
analysis of GWASstudies, with the effect size being the log natural of odds ratio (OR). The 
effect sizes calculated from studies on such large number of samples are yet not available in 
Pakistan, and the only available effect sizes of the SNPs are from studies on Caucasians. The 
effect sizes of the SNPs may vary among ethnicities as linkage disequilibrium and allele 
frequencies vary (Wang & Tao Elston, 2007). We therefore,used the unweighted GRS which 
is also the most commonly used one (Lluís-Ganella et al., 2010; Yiannakouris, Katsoulis, 
Trichopoulou, Ordovas, & Trichopoulos, 2014). The SNP coding (0,1,2) was adjusted in such 
a way that all the SNPs were positively associated with the outcome.  
We previously described the 19 SNPs score and a 13 SNPs score derived from it using only 
those SNPs present in genes/loci more robustly associated with CAD in the 
CARDIoGRAMplusC4D using 308 cases and 130 controls (Deloukas et al., 2013). The 
weighted GRS did not significantly differ between cases and controls and we found that the 
study may be adequately powered by increasing the samples to 340 cases and 340 controls 
(Beaney et al., 2015). Therefore, by increasing the number of samples (405 cases and 220 
controls) and genotyping two new SNPs, FTO rs9939609 and GLUL 10911021, the GRS 
became higher than previously reported and was significantly associated with CAD. We 
already have reported the association of FTO rs9939609 with CAD in Pakistani people which 
was independent of blood lipid levels (Shahid, Rehman, & Hasnain, 2016) and the SNP 
GLUL rs10911021 was reported to be v associated with CAD risk in type 2 diabetes mellitus 
(Prudente et al., 2015).  
In order to examine whether we have correctly genotyped the SNPs and to confirm the allele 
frequencies for these SNPs, we compared the allele frequencies of our subjects with PJL, 
which is a Pakistani Punjabi population from Lahore, in which 96 subjects were genotyped 
for many SNPs in the 1000 genomes project phase III (G. P. Consortium, 2012). The allele 
frequencies in our subjects did not significantly differ from those observed in PJL 
(Supplementary Table 8).  
In conclusion, the 21 SNPs risk score can be used for genetic risk analysis in the Pakistani 
people but the results need to be replicated with bigger sample sizes and meta-analysis of 
individual SNPs for CAD association in the Pakistani population. The GRS of these 21 loci is 
also strongly associated with lipid profile, suggesting that the mechanism of these risk SNPs 
is likely to be in part at least through creating a more atherogenic lipid profile in subjects 
carrying high numbers of risk alleles.  
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Table 1:Observed coronary artery disease odds ratio of the studied SNPs. 
Gene SNP OR C.I p-value 
MIA3 rs17465637 1.14 0.89-1.5 0.29 
CDKN2A rs10757274 1.18 0.93-1.5 0.17 
DAB2IP rs7025486 1.01 0.79-1.3 0.91 
CXCL12 rs1746048 1.22 0.95-1.6 0.12 
ACE rs4341 1.22 0.97-1.5 0.09 
NOS3 rs1799983 1.15 0.86-1.5 0.33 
APOA5 rs662799 1.02 0.75-1.4 0.9 
SMAD3 rs17228212 1.22 0.91-1.6 0.19 
APOB rs1042031 1.62 1.1-2.4 *0.01 
CETP rs708272 1.03 0.82-1.3 0.81 
LPA rs3798220 2.2 0.24-19.63 0.49 
LPA rs10455872 1.25 0.49-3.2 0.64 
MRAS rs9818870 1.09 0.73-1.6 0.68 
LPL rs328 1.5 0.98-2.3 0.06 
LPL rs1801177 - - - 
SORT1 rs646776 1.2 0.92-1.5 0.19 
PCSK9 rs11591147 3.71 0.34-41.2 0.29 
APOE rs429358 1.14 0.79-1.65 0.48 
APOE rs7412 1 0.56-1.77 0.98 
GLUL rs10911021 1.3 1-1.6 0.053 
FTO rs9939609 1.43 1-2.1 *0.009 
OR: Odds ratio,*Statistically significant association of the SNP with CAD.  
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Table 2: Association of genetic risk score quintiles with CAD risk. 
*p:Inter quintile p-value. Analyses were adjusted for age, gender, BMI, hypertensive and 
diabetic status. 
 
Table 3:Lipid levels in subjects with increasing number of genetic risk score alleles. 
Gene score Number TC±SD LDL-C±SD HDL-C±SD TG±SD 
9 1 135.6 79.5 72.2 155.7 
11 8 150.3±10.3 82.3±21 71.3±16.3 156.1±37 
12 11 170.3±28.6 88.6±12.8 66.1±19.5 175.8±44.1 
13 20 185.1±33.5 90.6±21.4 62.8±11.8 196.1±74.2 
14 48 190.2±40.3 94.1±26 58.1±12.6 203.7±65.2 
15 65 195.8±48.8 95.8±25.8 60.9±17.1 205.9±62.4 
16 87 196.3±43.8 98.4±25 53.1±15.8 205±71.9 
17 98 196.3±35.4 98.7±26.7 55.3±17.9 205.7±76.8 
18 97 191.6±40.1 101.4±29.8 49.7±13.7 207.6±54.4 
19 84 196±44.6 101.8±27.5 48.9±17.3 210.3±71.8 
20 40 207.9±55 114.4±28.3 48.7±16.4 215.2±49.4 
21 32 214.8±50 124.6±25.4 48.3±15.6 219.8±71.5 
22 23 218.2±55.5 134.3±23.3 46.5±14.7 231±45.1 
23 6 239.2±39.3 134.5±7.3 43.5±9.5 268.8±63.1 
24 1 243 143 39 280 
25 2 255.3±7.1 146.5±9.2 30±4.2 302.5±24.7 
  
Genetic risk ScoreQuintiles Allele ranges 
OR 
(95% CI) 
*p-value 
1 <13 1  
2 13 to 15 1.54 (0.99-2.38) 0.052 
3 15 to 16 
2.19 
(1.28-3.76) 
0.004 
4 16 to 17 
2.81 
(1.56-5.05) 
0.001 
5 >17 
2.96 
(1.71-5.13) 
<0.001 
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Table 4: Effect size of genetic risk score on blood lipid levels. 
Effect size (β)± standard error and p-values 
TC p-value LDL-C p-value HDL-C p-value TG p-value 
3.7±0.7 1.37x10-7 4±0.5 1.9x10-20 2±.3 3.6x10-15 4.2±1 7.1x10-5 
β is the increase/decrease in lipid levels perallele increase in genetic risk score . 
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Supplementary Table 1: Basic features of the SNPs used for gene score 
Gene Chromosome SNP number 
Base 
change 
Risk 
allele 
SNP type References 
MIA3 1q41 rs17465637 C>A C GWAS 
(Kathiresan et al., 
2009) 
CDKN2A 9p21,3 rs10757274 A>G G GWAS 
(Kathiresan et al., 
2009) 
DAB2IP 9q33,2 rs7025486 G>A A GWAS 
(Harrison et al., 
2012) 
CXCL12 10q11,21 rs1746048 C>T C GWAS (Samani et al., 2007) 
ACE 17q23,3 rs4341 C>G G Candidate 
(Casas, Cooper, 
Miller, Hingorani, & 
Humphries, 2006) 
NOS3 7q36,1 rs1799983 G>T T Candidate (Casas et al., 2006) 
APOA5 11q23,3 rs662799 A>G G Candidate 
(Sarwar & N Sandhu 
M.S, 2010) 
SMAD3 15q22,33 rs17228212 T>C C GWAS (Samani et al., 2007) 
APOB 2p24,1 rs1042031 G>A G Candidate 
(J. Casas, P et al., 
2006) 
CETP 16q13 rs708272 C>T C Candidate 
(J. Casas, P et al., 
2006) 
LPA 6q25,3 rs3798220 T>C C Candidate (Clarke et al., 2009) 
LPA 6q26 rs10455872 A>G G Candidate (Clarke et al., 2009) 
MRAS 3q22,3 rs9818870 C>T T GWAS 
(Erdmann et al., 
2009) 
LPL 8p21,3 rs328 C>G C Candidate 
(J. Casas, P et al., 
2006) 
LPL 8p21,3 rs1801177 G>A A Candidate (Sagoo et al., 2008) 
SORT1 1p13,3 rs646776 A>G A Candidate 
(Kathiresan et al., 
2009) 
PCSK9 1p32,3 rs11591147 G>T G Candidate 
(Benn, Nordestgaard, 
Grande, Schnohr, & 
Tybjærg-Hansen, 
2010) 
APOE 19q13,32 rs429358 T>C C Candidate (Bennet et al., 2007) 
APOE 19q13,32 rs7412 C>T T Candidate (Bennet et al., 2007) 
GLUL 1q25,3 rs10911021 C>T C Candidate (Qi et al., 2013) 
FTO 16q12,2 rs9939609 T>A A Candidate (Frayling et al., 2007) 
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Supplementary table 2: List of primers and probes used in TaqMan assay 
Gene SNP 40x Primer & probe Sequence of primers 
eNOS 
(E289D) 
rs1799983 
ENOS_G894T_F Primers GGCTGGACCCCAGGAAA 
ENOS_G894T_R Primers CACCCAGTCAATCCCTTTGGT 
ENOS_G894T_VIC Probe VIC =T CCCAGATGATCCCCCA 
ENOS_G894T_FAM Probe FAM=G CCAGATGAGCCCCCA 
SMAD3 rs17228212 
CT17228212_F Primers TCACACTGTCTTTGCCGTCATT 
CT17228212_R Primers AGGGACGTGTCCTCACTCA 
CT17228212_VIC Probe VIC = C AGTTAGGTTGCGAGTTC 
CT17228212_FAM Probe FAM = T TTAGGTTGCAAGTTC 
APOB 
(E4154K) 
rs1042031 
GA1042031_F Primer GGATAACGTGTTTGATGGCTTGGTA 
GA1042031_R Primer ATCAATGAGTGAGTCAATCAGATGCTT 
GA1042031_V Probe VIC =G AGTTACTCAAGAATTCCA 
GA1042031_M Probe FAM=A AGTTACTCAAAAATTCCA 
LPA 
(I1891M) 
rs3798220 
LPA_I1891M-205F Primers CACCAAGAAGTGAACCTCGAATCT 
LPA_I1891M-205R Primers TGTGTGGGCTCCAAGAACAG 
LPA_I1891M-205V1 Probe VIC = A CATGTTCAGGAAATAGAAGT 
LPA_I1891M-205M1 Probe FAM =G ATGTTCAGGAAATGGAAGT 
LPA rs10455872 
TC10455872_F Primers GTCTTGGGTAACAAGTGAAGGATATCT 
TC10455872_R Primers ACACATAGCTTTTCAGACACCTTGT 
TC10455872_V Probe VIC = A CTCAGAACCCAATGTGTTT 
TC10455872_M Probe FAM = G CAGAACCCAGTGTGTTT 
CELSR2/ 
PSRC1/ 
SORT1 
rs646776 
AG599839-143F Primers CTGGGTGACAGAGCAAGATTCT 
AG599839-143R Primers 
GCTTACTCTATGAGTCTTCATTTTTCTAA 
AATAAAGTG 
AG599839-143V1 Probe VIC = A CAGGATCAACTTCC 
AG599839-143M1 Probe FAM =G CAGGATCGACTTCC 
APOE 
112 
rs429358 
Pre -designed 
GCTGGGCGCGGACATGGAGGACGTG[C/T] 
GCGGCCGCCTGGTGCAGTACCGCGG 
C-3084793_20 Reverse chromosome 19 
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Supplementary table 3:List of primers and probes used in KASPar assay 
  
Gene SNP 
Sequence ( 50bp either side, allele label = [A/T], Other SNPs = 
N or IUPAC Code ) 
FAM VIC 
MIA3 rs17465637 
GAACCAAACCATATCACTTTTTAAAACCATAATAGTTA
TGCTGAGAAGTT[C/A]TTTTTTGTCATAGTGCAAGATA
ACATGTCTTTGCTGCTGATACATTGGGT 
C A 
CDKN2A rs10757274 
GGTATTACAAAAAGCTTCTCCCCCGTGGGTCAAATCTA
AGCTGAGTGTTG[A/G]GACNTAATTGAAATTCACTAGA
TAGATAGGAGATAGGGGTAGGGAATTCT 
A G 
DAB2IP rs7025486 
GGGNCTTGAGTGGTGAGCAAAGAGGGGAGAACAGCC
CCTGGCAGACCACT[A/G]GGAATCAAAGGAAGGATTTT
GAAAATAACAGGAATGATAACAGTGATCTC 
A G 
CETP rs708272 
TTTACCCCCTGACTCAACCCCCTAACCTGGCTCAGATC
TGAACCCTAACT[C/T]GAACCCCANTGATTCTGGGTCT
CAGACAAACACAAATCCCTATACCTGGC 
C T 
APOA5 rs662799 
AAGAGGCATCTGGGCCAGNGACTCTGAGCCCCAGGAA
CTGGAGCGAAAGT[A/G]AGATTTGCCCCATGAGGAAA
AGCTGAACTCCACTCGCAGGGCCTCTGAGG 
A G 
LPL 
(S474X) 
rs328 
GGCACCTGCGGTATTTGTGAAATGCCATGACAAGTCTC
TGAATAAGAAGT[C/G]AGGCTGGTGAGCATTCTGGGCT
AAAGCTGACTGGGCATCCTGAGCTTGCA 
C G 
MRAS rs9818870 
TCTCTTGCTGCNTTTTCACATCAGCTGTGCTGCTTGGTG
CCTCTCTGATA[C/T]NAATACACTGACACGTCAAAGTA
ACCTAATGTGGACACCATCCAGAAAAC 
C T 
APOE158 rs7412 
TGNNNAAGCTGNNTNAGCNGCTCCNCCNCGATGCCGA
TGACCTGCAGAAG[C/T]GCCTGGCAGTGTACCAGGCCG
GGNCCCGCGAGGGCGCCNAGCGCGGCCTC 
C T 
SLCO1B1 rs4149056 
NATCTACATAGGTTNTTTAAAGGAATCTGGGTCATACA
TGTGGATATNTG[T/C]GTTCATGGGTAATATGCTTNNT
GGAATAGGGGAGACTCCCATAGTACCANT 
T C 
CXCL12 rs1746048 
ATTTCAGGACTGAACAGAGACTGAGAAGGGTAAAGGG
TGGTAGGATTGAG[C/T]GAGTCAGGCCAGAAACCTCTA
GTTAGCTACCATGACAGAAGGGAAACATG 
C T 
ACE rs4341 
TCTCTGAGCTCCCCTTACAAGCAGARGTGAGCTAAGG
GCTGGARCTYAAG[C/G]CATTCMAMCCCCTACCAGAT
STGACGAATRTGATGGCCRCRTCCCGGAAA 
C G 
LPL rs1801177 
CAGTTAACCTCATATCYAATTTTTCCKTTCCAGAAAGA
AGAGATTTTATY[G/A]ACATYGRAAGTAAATTTGCCCT
AAGGAMCCCTGAAGWCACAGSTGARGAC 
G A 
PCSK9 rs11591147 
TGCGCAGGAGGACRAGGACGGCGACTACGAGGAGCT
GGTGCTAGCCTTGC[G/T]TTCYGAGGAGGACGGCCTGG
YCGAAGCACCCRAGCACGGAACCACASCCA 
G T 
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Supplementary table 4:Sequence of primers used in PCR 
Primer Sequence 
MIA3_F 5'-ATCCAATCACCTTCCACCAG-3' 
MIA3_R 5'-CCCAATGTATCAGCAGCAAA-3' 
CDKN2A_F 5'-GTTTCTGCACATGGTGATGG-3' 
CDKN2A_R   5'-CATTCCCCAACATTTGTCCT-3' 
DAB2IP_F 5'-GCAGATGGTGTGACTGGAAA-3' 
DAB2IP_R 5'-AACCCCTGGTGCTGTGTAAG-3' 
ACE_F   5'-CCCCTTACAAGCAGAGGTGA-3' 
ACE_R 5'-TCGGGTAAAACTGGAGGATG-3' 
CETP_F 5'-GTGACCCCCAACACCAAATA-3' 
CETP_R 5'-TCGCCTTCAAGGTCAAGTTC-3' 
APOA5_F 5'-GCAGGGTGAAGATGAGATGG-3'   
APOA5_R 5'-TAGACGGAGTGGGTGTGTCA-3' 
SMAD3_F 5'-CTCAGATCCTTTGCGGGTAG-3' 
SMAD3_R 5'-TCTTCTGTGCAGACCAGGTG-3' 
LPArs3798220_F 5'-GAAGGGGCTGGACCATATTT-3' 
LPArs3798220_R 5'-AAGACCACAGGTGAGCGAGT-3' 
eNOS_F 5'-ACTCCCCACAGCTCTGCAT-3' 
eNOS_R 5'-CAGTCAATCCCTTTGGTGCT-3' 
LPLrs328_F 5'-CTTCCACAGGGTGATCTTCTG-3' 
LPLrs328_R 5'-CATGAAGCTGCCTCCCTTAG-3' 
LPLrs180_F 5'-AAATAGCATCAGCGGTGGTT-3' 
LPLrs180_R 5'-ATGAGGTGGCAAGTGTCCTC-3' 
SLCO1B1_F 5'-GAATCTGGGTCATACATGTGG-3' 
SLCO1B1_R 5'-AAGGGAAAGTGATCATACAATTTAATA-3' 
PCSK9_F 5'-GACTACGAGGAGCTGGTGCT-3' 
PCSK9_R 5'-CCTGCACTCCACTTCCTCTC-3' 
MRAS_F 5'-TCTTGCTGCGTTTTCACATC-3' 
MRAS_R 5'-TTGACTCCAAGGGAAGATGG-3' 
APOB_F 5'-GCCCAGAATCTGTACCAGGA-3' 
APOB_R 5'-TGGAATCTGGGGAAGTTCAG-3' 
CXCL12_F 5'-GTCCAGATGAGGCCATCAAG-3' 
CXCL12_R 5'-TGCCAAGAAAATGACACAGC-3' 
LP(a)rs10455872_F 5'-GCATAGCCAGACATGGGTTT-3' 
LP(a)rs10455872_R 5'-TGCCATGTTTGTCTTGGGTA-3' 
CELSR2_F 5'-TGGTGAAAAGGACACCTTCC-3' 
CELSR2_R 5'-CTGTCCGCTTCTGTGTGGTA-3' 
APOE158_F   5'-CTGCGTAAGCGGCTCCTC-3' 
APOE158_R 5'-CTGCCCATCTCCTCCATC-3' 
APOE112_F 5'-GCCTACAAATCGGAACTGGA-3' 
APOE112_R 5'-CAGCTCCTCGGTGCTCTG-3' 
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Supplementary Table 5: Anthropometric and biochemical parameters of study subjects. 
Variables Cases Controls p-value 
Number 405 220 
 
Age (years) 59.1±12.6 56 ± 10.5 0.002 
Sex 
Males (n) 
Females (n) 
 
216 
189 
 
120 
100 
0.27 
Diabetes (%) 64.6 13.6 5.1x10-34 
Hypertension (%) 62.1 16.4 8.9x10-28 
Smoking (%) 29.5 10.5 7.3x10-08 
Total cholesterol 207.5±53.7 175.4±43 8.8x10-14 
Triglycerides 212.4±70 188±66.3 2.6x10-5 
LDL-C 106±28.9 84.7±17 6.3x10-22 
HDL-C 45.2±11.9 67.4±16.3 1.8x10-66 
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supplementary Table 6: Comparison of RAFs between cases and controls 
 
Gene 
 
SNP 
RAFs (C.I) 
Cases Controls p-value 
SORT1 rs646776 
0.75 
(0.72-0.78) 
0.72 
(0.67-0.76) 
0.19 
APOB rs1042031 
0.92 
(0.90-0.94) 
0.87 
(0.84-0.91) 
*0.007 
APOE rs429358 
0.12 
(0.10-0.14) 
0.11 
(0.08-0.13) 
0.46 
APOE rs7412 
0.04 
(0.03-0.05) 
0.04 
(0.02-0.06) 
0.98 
LPL rs328 
0.94 
(0.92-0.95) 
0.91 
(0.88-0.93) 
0.06 
LPL rs1801177 - - - 
APOA5 rs662799 
0.17 
(0.14-0.20) 
0.167 
(0.13-0.20) 
0.89 
CETP rs708272 
0.551 
 (0.52-0.59) 
0.543 
(0.50-0.59) 
0.8 
LPA rs3798220 
0.005 
 (0.0-0.01) 
0.002 
(0.00-0.01) 
0.66 
LPA rs10455872 
0.017 
 (0.01-0.03) 
0.014 
(0.00-0.02) 
0.81 
CDKN2A rs10757274 
0.505 
(0.47-0.54) 
0.463 
(0.42-0.51) 
0.162 
MIA3 rs17465637 
0.651 
 (0.62-0.68) 
0.621 
(0.58-.67) 
0.292 
DAB2IP rs7025486 
0.318 
 (0.29-0.35) 
0.315 
(0.27-0.36) 
0.913 
SMAD3 rs17228212 
0.207 
(0.18-0.23) 
0.176 
(0.14-0.21) 
0.19 
MRAS rs9818870 
0.094 
 (0.07-0.11) 
0.087 
(0.06-0.11) 
0.67 
CXCL12 Rs1746048 
0.675 
 (0.64-0.71) 
0.63 
(0.58-0.68) 
0.114 
ACE rs4341 
0.577 
(0.54-0.61) 
0.525 
(0.48-0.57) 
0.079 
NOS3 rs1799983 
0.202 
(0.17-0.23) 
0.178 
(0.14-0.21) 0.312 
PCSK9 rs11591147 
0.999 
(1-1) 
0.995 
(0.99-1) 
0.252 
GLUL rs10911021 
0.68 
(0.64-0.70) 
0.62 
(0.61-0.70) 
0.055 
FTO rs9939609 
0.35 
(0.32-0.39) 
0.28 
(0.25-32) 
*0.003 
C.I: Confidence interval, RAFs: Risk allele frequencies, * significantly high RAF in cases than 
controls.   
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Supplementary Table 7: Genetic risk score in cases and controls and its association with 
CAD. 
Mean gene score Cases Controls p-value OR 95% C.I p-value 
Un-weighted 17.53±2.52 16.64±2.44 2.4x10-5 1.16 1.08-1.23 <0.0001 
All the analyses were adjusted for age, gender, BMI, hypertensive and diabetic status, 
supplementary Table 8: Comparison of risk allele frequencies in studied samples with 
Pakistani Punjabi population from Lahore (PJL) in 1000 genomes project phase III. 
 
Gene 
 
SNP 
Risk allele frequencies 
Current study PJL *p-value 
MIA3 rs17465637 0.64 0.62 0.5 
CDKN2A rs10757274 0.49 0.495 0.9 
DAB2IP rs7025486 0.317 0.26 0.1 
CXCL12 rs1746048 0.659 0.635 0.5 
ACE rs4341 0.559 0.63 0.06 
NOS3 rs1799983 0.193 0.151 0.2 
APOA5 rs662799 0.169 0.151 0.5 
SMAD3 rs17228212 0.196 0.13 0.03 
APOB rs1042031 0.905 0.906 0.9 
CETP rs708272 0.548 0.547 0.97 
LPA rs3798220 0.004 0.005 0.81 
LPA rs10455872 0.016 0.005 0.25 
MRAS rs9818870 0.091 0.115 0.31 
LPL rs328 0.925 0.948 0.26 
LPL rs1801177 0 0 
 
CELSR2 rs646776 0.739 0.745 0.87 
PCSK9 rs11591147 0.998 0 0.5 
APOE rs429358 0.114 0.083 0.2 
APOE rs7412 0.04 0.036 0.77 
* is p value between risk allele frequencies in subjects from this study and that of from PJL.   
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Supplementary Figure 1: Histogram showing comparison of genetic risk score in cases and 
controls. 
Controls 
Cases 
Genetic risk score 
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                   Supplementary Figure 2: Receiver operator curve, area under ROC=0.602 (C.I=0.56-0.65, 
P<0.001).  
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